Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2021-02-25 Annual Report
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Preliminary Final Report 10 pages 137.2KB
Annual Report Classification · 95% confidence The document is titled 'Lifespot Health Ltd Appendix 4E Preliminary final report' and covers the financial year ended 31 December 2020. It includes detailed financial statements such as the statement of profit or loss, statement of financial position, statement of changes in equity, statement of cash flows, and notes to the financial statements. The document contains comprehensive financial data and analysis for the full fiscal year, including revenues, losses, assets, liabilities, equity, and cash flows. The presence of a full set of financial statements and notes indicates this is a full annual financial report rather than a brief announcement or a certification. The document is not a short announcement or a certification letter, so it is not classified as RPA or RNS. The document is not an interim or quarterly report as it covers a full year. The document is not an earnings release or investor presentation. The document is a full annual report equivalent, consistent with the definition of an Annual Report (10-K). Therefore, the appropriate classification is Annual Report (10-K). FY 2020
2021-02-25 English
Appendix 4C - quarterly 5 pages 216.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements including operating, investing, and financing activities for the quarter ended 31 December 2020. It includes actual financial data such as cash flows, reconciliation of cash and cash equivalents, payments to related parties, and financing facilities. The document is over 10,000 characters, indicating it is a substantive report rather than a brief announcement. The content aligns with a quarterly financial report rather than an annual report or earnings release. The presence of detailed cash flow statements and compliance statements confirms it is an Interim / Quarterly Report (IR). Q2 2020
2021-01-28 English
Quarter 4 Update 3 pages 257.8KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 29 January 2021, titled 'Quarterly Activities, Cashflow Report and Operations Update' for the quarter ended 31 December 2020. It contains detailed financial and operational data for the quarter, including cash reserves, cash flow from operating activities, capital raising details, sales updates, R&D expenses, payments to directors, and use of funds. The presence of substantive financial data and operational analysis for a quarter indicates this is a comprehensive interim/quarterly report rather than a brief announcement or a simple earnings release. The document length (6450 characters) supports it being a full report rather than a short announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2020
2021-01-28 English
Becoming a substantial holder 3 pages 156.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 filed under the Corporations Act 2001 Section 671B, titled 'Notice of initial substantial holder.' It details the substantial shareholding of Ela Capital Inc. in Lifespot Health Ltd., including voting power, relevant interests, registered holders, consideration paid, and associates. This form is a regulatory disclosure of a major shareholding event, specifically notifying the market and regulators about a substantial holder crossing a voting power threshold. It is not a financial report, earnings release, or management report. It is a notification of a change in significant share ownership levels, which fits the definition of 'Major Shareholding Notification' (MRQ). The document length and content confirm it is the actual notification, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2021-01-19 English
Appendix 2A 14 pages 238.0KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being quoted, and references to previous announcements such as Appendix 3B. This form is a regulatory filing used to notify the exchange about new securities being listed or changes in securities status. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement since it contains substantive information about the securities quotation application. Therefore, the document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-01-18 English
Placement of Rights Issue Shortfall 1 page 140.7KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement dated 19 January 2021 regarding the completion of a placement and closing of a shortfall offer pursuant to a recent rights issue. It details the number of shares placed, the price, the strategic investor involved, and the resulting shareholding percentage. There are no financial statements or detailed financial analysis present, and the document is relatively short (1826 characters). This is a clear update on a capital raising activity, specifically a rights issue placement, which fits the category of Capital/Financing Update (CAP).
2021-01-18 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.